Document |
Document Title |
WO/2023/147297A2 |
The present invention relates, in part, to methods, compounds, and compositions of a DDR pathway inhibitor in combination with a dual RAF/MEK inhibitor, for treating abnormal cell growth (e.g., cancer).
|
WO/2023/143582A1 |
Disclosed is a fusion protein comprising: (i) an antibody fragment; (ii) a linker fragment; and (iii) a photosensitive protein; wherein the antibody fragment binds with the photosensitive protein by means of the linker fragment, the anti...
|
WO/2023/141659A2 |
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib has significantly prolonged progression-free survival (PFS) in EGFR-mutant lung cancer patients, including those with brain metastases. However, osim...
|
WO/2023/140629A1 |
The present invention relates to a 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound having protein kinase inhibitory activity, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for preventing, alleviating...
|
WO/2023/141606A2 |
Compositions which treat lysosomal deficits in lysosomal storage disorders, neuronal ceroid lipofuscinosis, idiopathic/ sporadic brain disorders that include neurological and psychiatric disorders, include agents such as troglitazone, ro...
|
WO/2023/141609A2 |
Methods and apparatuses for treating inflammatory diseases by neurostimulation in patients who have failed to adequately respond or have become intolerant to a drug therapy (such as a TNF inhibitor and/or a JAK inhibitor).
|
WO/2023/141125A2 |
Provided herein are methods of reversing accumulation of a serine protease, reversing cellular damage, and/or preserving extracellular matrix in an organ of a subject comprising selecting a subject at risk of damage to the organ, and adm...
|
WO/2023/141631A2 |
Improved methods for treating ophthalmic disorders, particularly those associated with ocular hypertension and glaucoma. Methods of treatment and pharmaceutical compositions for treatment of ophthalmic disorders employing one or more bet...
|
WO/2023/137440A2 |
The present disclosure is directed to methods for treating immunological diseases and disorders with upadacitinib. The methods include adjusting the dose of upadacitinib in patients with severe renal impairment, in patients concurrently ...
|
WO/2023/133961A1 |
A high sensitivity hydrogen sulfide responsive nanoprobe and a preparation method therefor. A preliminary attempt to the application of a nano fluorescent probe in the second near-infrared region is made. Compared with a common probe, th...
|
WO/2023/133937A1 |
A near-infrared nano photosensitizer, a preparation method therefor and the use thereof. The present invention relates to the technical field of photosensitizers. In the near-infrared nano photosensitizer, a conjugate extension modificat...
|
WO/2023/137469A2 |
Methods for diagnosing atopic dermatitis (AD) by using thrombin and/or fibrinogen as biomarkers to determine the presence or severity of AD. Also provided are methods for treating AD by administering to a subject an effective amount of a...
|
WO/2023/133409A2 |
Described herein are methods and compositions that include use of one or more PARP1 inhibitors and one or more inhibitors of activated stromal / activated cancer-associated fibroblasts. Such methods and compositions are useful for treati...
|
WO/2023/133412A2 |
A composition with enhanced antiviral activity against coronavirus comprising Luteolin or a pharmaceutically acceptable salt thereof, and one or more salts selected from the group consisting of magnesium salts, manganese salts, zinc salt...
|
WO/2023/133538A2 |
Described herein are methods of treating inflammatory diseases or conditions such as inflammatory bowel diseases including Crohn's disease and ulcerative colitis, the methods comprising administering a TL1A inhibitor and an IL23 inhibito...
|
WO/2023/133414A2 |
Disclosed are methods of treating diseases or disorders associated with cellular senescence as well as methods of inducing ferroptosis in senescent cells. The methods include administering a compound that induces ferroptosis.
|
WO/2023/133371A2 |
This invention provides compositions of (a) LB-100 or an LB-100 ester, or a pharmaceutically acceptable salt thereof, and (b) a WEE1 kinase inhibitor, checkpoint kinase 1 ("CHK1") inhibitor, B-cell lymphoma-extra large ("BCL-xL") inhibit...
|
WO/2023/133418A2 |
Provided herein are methods and compositions for reducing the proviral effect of a virus-derived circular RNA on a target cell through the use of an agent that blocks a proviral function of the virus-derived circular RNA. Also, provided ...
|
WO/2023/130514A1 |
A coordination polymer nano material having a combined photodynamic-starvation therapy function, a preparation method therefor and an application thereof. The coordination polymer nano material comprises a carrier and an enzyme. The enzy...
|
WO/2023/133505A2 |
Methods and compositions for treating leukemia involving administering a therapeutically effective amount of an inhibitor of indoleamine 2,3 dioxygenase (IDO1). The leukemia may be is acute myeloid leukemia or acute lymphoid leukemia. Th...
|
WO/2023/133053A2 |
Methods and systems for the induction of ferroptosis in a tissue in a subject are provided. Various ferroptosis-inducing agents a described. Various methods of administration are described for optimal ferroptosis induction and killing of...
|
WO/2023/129535A2 |
This invention contemplates combined use of a rose bengal (RB ) derivative with irradiation of bacteria with light to treat and kill the irradiated bacteria. In one aspect, Gram-positive bacteria are treated in a method in which the bact...
|
WO/2023/130149A2 |
The present disclosure is directed to compounds and compositions for treating gut motility disorders such as, for example, achalasia, Hirschsprung's disease, an intestinal pseudo-obstruction, gastroesophageal reflux disease (GERD), funct...
|
WO/2023/129874A2 |
The embodiments of the present invention provide methods for the treatment of glioblastoma that minimize radiation damage in susceptible patients, such as the elderly. Patients with one or more diagnostic marker of α-synucleinopathy, or...
|
WO/2023/129899A2 |
Compositions and methods are provided for treatment of pathologies associated with Tau protein, including methods wherein DRB1*04-mediated adaptive immune response against Tau protects against PD, AD, ALS and tauopathies.
|
WO/2023/130150A2 |
The present disclosure relates generally to two-dimensional and three-dimensional cultures of cells, the cultures comprising one or a plurality of enteric neurons and/or one or a plurality of enteric glial cells. These cells and cultures...
|
WO/2023/129947A2 |
Methods of lowering blood glucose and treating Type 2 diabetes in a subject by increasing expression or activity of phosphodiesterase 4D isoform 3 (PDE4D3) in adipocytes of the subject are described. In some instances, expression of PDE4...
|
WO/2023/122185A2 |
The present disclosure relates to the use of therapeutic agents to prevent and/or treat neurodegenerative disorders. The methods include prevention and/or treatment of neurodegenerative disorders with the administration of the disclosed ...
|
WO/2023/121271A1 |
A nanocomposite for drug delivery is provided. The nanocomposite for drug delivery comprises: a sol-gel transition polymer; a drug carrier which is provided on the sol-gel transition polymer and has a drug loaded therein; and a magnetic ...
|
WO/2023/122555A2 |
Disclosed herein is a method of treating human chronic hepatitis B virus infection by reducing or eliminating cccDNA in liver cell of an HBV infected patient for 3 months or longer.
|
WO/2023/122469A2 |
Disclosed herein are methods of treating chemosensory dysfunction in a subject, comprising administering to the subject a device such as a stent comprising a phosphodiesterase inhibitor. Also disclosed herein are devices comprising phosp...
|
WO/2023/117695A1 |
The present invention relates to a composition comprising a temperature sensitive biocompatible solder and at least one type of nanoparticles, characterized in that a first type of nanoparticles is a fluorescent nanothermometer, wherein ...
|
WO/2023/118085A1 |
The present disclosure relates to methods of treating a brain tumour or a neuroblastoma in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a substituted azaquinolone com...
|
WO/2023/109836A1 |
Disclosed is an ultrasonically-enhanced continuous and large-scale production method for nano-formulations. Specifically disclosed is a preparation system for continuous production of nano-formulations, comprising (a) a first pipe, (b) a...
|
WO/2023/111396A1 |
A pharmaceutical composition is disclosed. The pharmaceutical composition may comprise boronophenylalanine (BPA) or a pharmaceutically acceptable salt thereof and a 2-hydroxy amine compound (2HA) or a pharmaceutically acceptable salt the...
|
WO/2023/114867A2 |
Disclosed are methods of treatment and inhibitors for gastrointestinal stromal tumor (GIST) in a subject, with an active agent that inhibits a Menin or a member of the Menin-MLL complex.
|
WO/2023/109694A1 |
Disclosed is a method for enhancing the activity of a photosensitizer by means of a magnetic field. In the method, under an illumination condition, the photosensitizer is placed in a magnetic field, which can improve the cytotoxicity of ...
|
WO/2023/114945A2 |
Compositions for and methods of treating lung conditions, such as those associated with elevated cytokines, are described. The methods include administration of vandetanib or a pharmaceutically acceptable salt thereof. Methods of treatin...
|
WO/2023/114466A1 |
In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to th...
|
WO/2023/109701A1 |
A method for synthesizing an AIE nanoprobe, the AIE nanoprobe prepared by means of the method, and a kit.
|
WO/2023/113843A2 |
Borylated Di-Peptide Amino Acid ("Bdi-AA") compositions and Di-Peptide Amino Acid (di-AA) compositions and methods of making Bdi-AAs and di-AAs are disclosed herein. Consequently, the Bdi-AAs and di-AAs can be administered to patients as...
|
WO/2023/114772A2 |
Disclosed herein are small molecule drugs that reduce protein aggregation and their methods of use. One aspect of the invention provides for a method reducing aggregate protein abundance in a protein aggregate, the method comprising admi...
|
WO/2023/107893A2 |
The present disclosure provides compositions and methods for treating a mammalian subject for a neurodegeneration disease, including amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia 2 (SCA2). Aspects of the composition incl...
|
WO/2023/104124A1 |
A sonosensitizer, which is prepared by means of a simple process, overcomes the anoxic microenvironment of tumors by using the characteristic of producing oxygen by means of photosynthesis of cyanobacteria after illumination, and can exe...
|
WO/2023/108071A2 |
Disclosed herein are methods for treating or preventing amyotrophic lateral sclerosis (ALS) in a subject in need thereof. The method comprises isolating RNAs from a sample obtained from the subject; characterizing the RNAs and their rela...
|
WO/2023/108110A2 |
The present invention relates, in part, to methods, compounds, and compositions of an autophagy pathway inhibitor in combination with a dual RAF/MEK inhibitor, for treating abnormal cell growth (e.g., cancer).
|
WO/2023/105290A1 |
Sonodynamic therapy systems and methods use short, high-pressure ultrasound pulses that produce small (and therefore clinically safe) increases (up to 1-2 °C) in tissue temperature but nonetheless activate sonodynamic agents, allowing i...
|
WO/2023/097854A1 |
A 7-ethyl-10-hydroxycamptothecin prodrug having fluorescence activity, a preparation method therefor and the use thereof are disclosed. The 7-ethyl-10-hydroxycamptothecin prodrug (BDP-SN38) with fluorescence activity is prepared by carry...
|
WO/2023/098007A1 |
An intelligent conversion double-stimuli-responsive probe chelated with metal ions, and a preparation method therefor and the use thereof. The probe can be self-assembled into large nanoparticles in a water buffer solution, and the large...
|
WO/2023/102446A2 |
Methods for treating vitiligo in a patient in need thereof, methods of inducing repigmentation in skin, methods for preventing further loss of pigmentation in a patient having vitiligo, and methods of reducing symptoms of vitiligo, where...
|